Allopurinol in dermatology

American Journal of Clinical Dermatology

Volumn 11, Issue 4, 2010, Pages 225-232

  Tsai, Tsen Fang ^a   Yeh, Ting Yu ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOPHYLLINE; AMOXICILLIN; AMPICILLIN; ASCOMYCIN; AZATHIOPRINE; BENAZEPRIL; CAPTOPRIL; CHLORPROPAMIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICOUMAROL; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; MEGLUMINE ANTIMONATE; MERCAPTOPURINE; MINOCYCLINE; OXIPURINOL; POLY(METHYL METHACRYLATE); SILICON; SULFINPYRAZONE; TACROLIMUS; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE; WARFARIN; XANTHINE OXIDASE;

ABDOMINAL SURGERY; ACUTE HEMORRHAGIC PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOIMMUNE SKIN DISEASE; BEHCET DISEASE; CARDIOVASCULAR FUNCTION; CELL FUNCTION; CHRONIC PANCREATITIS; CHRONIC PROSTATITIS; COLLAGEN DISEASE; CONGESTIVE HEART FAILURE; DISEASE PREDISPOSITION; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME INHIBITION; ESOPHAGUS STRICTURE; FACE EDEMA; FOLLICULITIS; FOOT ULCER; FOREIGN BODY GRANULOMA; GOUT; GRANULOMA; GRANULOMA ANNULARE; HEART FAILURE; HERPES LABIALIS; HLA SYSTEM; HUMAN; HYPERURICEMIA; KYRLE DISEASE; MACULOPAPULAR RASH; NERVE FUNCTION; OFF LABEL DRUG USE; PITYRIASIS ROSEA; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; RASH; REACTIVE PERFORATING COLLAGENOSIS; REVIEW; SARCOIDOSIS; SCLERODERMA; SKIN DISEASE; SKIN GRANULOMA; SKIN LEISHMANIASIS; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ALLOPURINOL; ANIMALS; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; DRUG INTERACTIONS; EPIDERMAL NECROLYSIS, TOXIC; GOUT SUPPRESSANTS; HUMANS; OFF-LABEL USE; SKIN DISEASES; STEVENS-JOHNSON SYNDROME;

EID: 77953007950     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11533190-000000000-00000     Document Type: Review

References (69)

1. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout: British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Oxford: Oxford University Press, 2007
2. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114
3. Rx care Canada. Allopurinol [online]. Available from URL: http:// www.rxcarecanada.com/Allopurinol.asp [Accessed 2008 Oct 3]
4. Gorrie M, Beaman M, Nicholls A, et al. Drug points: allopurinol interaction with cyclosporine. BMJ 1994; 308: 113
5. University of Maryland Medical Centre, Complementary Medicine. Allopurinol [online]. Available from URL: http://www.umm.edu/altmed/drugs/ allopurinol-002400.html [Accessed 2008 Oct 3]
6. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751
7. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516
8. Mittal A, Phillips AR, Loveday B, et al. The potential role for xanthine oxidase inhibition in major intra-abdominal surgery. World J Surg 2008; 32: 288-295
9. Comert B, Isik AT, Aydin S, et al. Combination of allopurinol and hyperbaric oxygen therapy: a new treatment in experimental acute necrotizing pancreatitis? World J Gastroenterol 2007; 13: 6203-6207
10. Tasci I, Deveci S, Isik AT, et al. Allopurinol in rat chronic pancreatitis: effects on pancreatic stellate cell activation. Pancreas 2007; 35: 366-371
11. Makay O, Yukselen V, Vardar E, et al. Role of allopurinol on oxidative stress in caustic burn: cure for stricture? Pediatr Surg Int 2007; 23: 1105-1112
12. Inkster ME, Cotter MA, Cameron NE. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol 2007; 561: 63-71
13. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-234
14. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226
15. McNaughton CO, Wilt T. Allopurinol for chronic prostatitis. Cochrane Database Syst Rev 2000; (4): CD001041
16. Lara DR, Cruz MR, Xavier F, et al. Allopurinol for the treatment of aggressive behaviour in patients with dementia. Int Clin Psychopharmacol 2003; 18: 53-55
17. Rx List: The Internet Drug Index. Zyloprim-drug interaction [online]. Available from URL: http://www.rxlist.com/zyloprim-drug.htm [Accessed 2008 Oct 3]
18. Drug InformationOnline.Allopurinol drug interactions [online].Available from URL: http://www.drugs.com/drug-interactions/allopurinol-d00023.html [Accessed 2008 Oct 3]
19. MedicineNet.com. Allopurinol-drug interactions [online]. Available from URL: http://www.medicinenet.com/allopurinol-oral/page2.htm [Accessed 2008 Oct 3]
20. Hamanaka H, Mizutani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol 1998; 23: 32-34
21. Markel A. Allopurinol hypersensitivity and DRESS syndrome. Am J Med 2008; 121: 235: e25
22. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J 2005; 7: 656-660
23. Ichiche M, Kiesch N, Bels D. DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med 2003; 14: 498-500
24. Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083-1084
25. Masaki T, Fukunaga A, TohyamaM, et al. Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol 2003; 83: 128-131
26. Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-304
27. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5
28. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a Severityof-Illness Score for Toxic Epidermal Necrolysis. J Invest Dermatol 2000; 115: 149-153
29. Ooi CG, Walker P, Sidhu SK, et al. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol 2006; 47: 270-273
30. Yu RC, Chu TC. Allopurinol-induced toxic pustuloderma. Br J Dermatol 1993; 128: 95-98
31. Becker D, Enk A, Bräuninger W, et al. Granuloma annulare disseminatum as a rare side effect of allopurinol [in German]. Hautarzt 1995; 46: 343-345
32. Bouloc A, Reygagne P, Lecoz P, et al. Perforating foot ulceration with allopurinol therapy. Clin Exp Dermatol 1996; 21: 351-352
33. Atzori L, Pinna AL, Ferreli C, et al. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 2006; 12: 1
34. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32
35. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.NEngl J Med 1995; 333: 1600-1607
36. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139
37. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005; 35: 188-190
38. Hung SI, Chung WH, Chen YT. Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor. Drug hypersensitivity. 1st ed. Basel: Karger, 2007: 55-64
39. Dainichi T, Uchi H, Moroi Y, et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007; 215: 86-88
40. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107
41. Hoque SR, Ameen M, Holden CA. Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol. Br J Dermatol 2006; 154: 759-762
42. Querings K, Balda BR, Bachter D. Treatment of acquired reactive perforating collagenosis with allopurinol. Br J Dermatol 2001; 145: 174-176
43. Faver IR, Daoud MS, Su WPD. Acquired reactive perforating collagenosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30: 575-580
44. Munch M, Balslev E, Jemec GB. Treatment of perforating collagenosis of diabetes and renal failure with allopurinol. Clin Exp Dermatol 2000; 25: 615-616
45. Antony F, Layton AM. A case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 2000; 142: 1052-1053
46. Samuel M, Allen GE, McMillan SC, et al. Sarcoidosis: initial results on six patients treated with allopurinol [conference abstract]. Br J Dermatol 1984; 111 Suppl. 26: 20
47. Brechtel B, Haas N, Henz BM, et al. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol 1996; 135: 307-309
48. Reisberger EM, Landthaler M, Wiest L, et al. Foreign body granulomas caused by polymethylmethacrylate microspheres successful treatment with allopurinol. Arch Dermatol 2003; 139: 17-20 (Pubitemid 36091569)
49. Redondo P, Del Olmo J, Alberola I. In situ and distant foreign body granulomas caused by silicone: treatmentwith allopurinol. Br J Dermatol 2005; 152: 1062-1094
50. Martin JM, Revert A, Monteagudo C, et al. Granulomatous reactions to permanent cosmetic tattoos successfully treated with topical steroids and allopurinol. J Cosmet Dermatol 2007; 6: 229-231
51. Fischer J, Metzler G, Schaller M. Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies. Arch Dermatol 2007; 143: 505-510
52. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-524
53. Rakhmatov AB. Allopurinol in the treatment of psoriasis patients. Vestn Dermatol Venerol 1986; 1: 58-59
54. Feuerman EJ, Nir MA. Allopurinol in psoriasis: a double-blind study. Br J Dermatol 1973; 89: 83-86
55. Yokomizo H, Yoshimatsu K, Hashimoto M, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-FU therapy-induced stomatitis. Anticancer Res 2004; 24: 1131-1134
56. El-Farrash MA, Youssef JM, El-Mongy SE. Allopurinol as a potential therapeutic agent for recurrent herpes labialis. J Med Dent Sci 2003; 50: 147-154
57. Mazzatenta C, Ghilardi A, GrazziniM. Treatment of disseminated granuloma annulare with allopurinol: case report. Dermatol Ther 2010; 23 Suppl. 1: S24-7
58. Shih CJ, Tsai TF, Chen YF, et al. Kyrle's disease successfully treated with allopurinol. Int J Dermatol. In press
59. Rodemer Y. Use of allopurinol for the treatment of palmo-plantar erythrodysesthesia. Poster no.128 presented at the 10th World Congress on Gastrointestinal Cancer; 2008 Jun 25-28; Barcelona
60. Lonn E, Factor SM, van Hoeven KH, et al. Effects of oxygen free radicals and scavengers on the extracellular collagen matrix during ischaemia- reperfusion. Can J Cardiol 1994; 10: 203-213
61. Kim C, Long WT. Sarcoidosis. Dermatol Online J 2004; 10: 24
62. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004; 3: 2-15
63. Namazi MR. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. JEADV 2005; 19: 319-322
64. Mizuno K, Okamoto H, Horio T. Cutaneous biology inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesionmolecules and purinergic receptors. Br JDermatol 2004; 150: 205-210
65. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol 2002; 27: 585-590
66. Viglioglia PA, Plante GE, Viglioglia J, et al. Allopurinol in psoriasis. Dermatologica 1970; 141: 203-207
67. Wachowicz B, Olas B, Zbikowska HM, et al. Generation of reactive oxygen species in blood platelets. Platelets 2002; 13: 175-182
68. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342: 83-84
69. Namazi MR. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int Immunopharmacol 2004; 4: 349-353